Effects of Fuzhenghuayu Capsule on Myocardial Fibrosis in Rats with Myocardial Infarction

Objective: Acute myocardial infarction is one of the major diseases endangering human health.Myocardial fibrosis is the microscopic pathological mechanisms that caused by the structure of the heart damage,heart dysfunction,arrhythmia,heart failure and even sudden death after myocardial infarction.Prevention of myocardial fibrosis is the focus of current medical research and hotspots.The purpose of this study is to investigate the effects of Fuzhenghuayu capsule on myocardial fibrosis in rats with myocardial infarction.Methods: Rats were randomly divided into Sham operation group,model group,Fuzhenghuayu capsule(FZHY) group and captopril group.MI model of rats was established by ligating left anterior descending coronary artery,and rats in Sham operation group were only punctured without ligating.Rats were treated with corresponding drugs for two months from 10 days after modeling.After treatment left ventricular infarct size and myocardial collagen area were measured.Results: Compared with sham operation group,the non-infarcted area decreased remarkably in the model group,FZHY group and captopril group(P0.01).Compared with model group,the infarct area and the percentage of infarct size decreased significantly in FZHY group and captopril group(P0.05,P0.01).When it comes to expressions of myocardial collagen,compared with sham operation group,the left ventricular myocardial collagen expression area increased significantly in model group and FZHY group.Compared with model group,the myocardial collagen expression area decreased significantly in FZHY group and captopril group(P0.05,P0.01).Conclusion: Fuzhenghuayu capsule can improve myocardial ischemia,reduce the scope of myocardial infarction and inhibit the expression of myocardial collagen.In addition to the treatment of liver fibrosis,Fuzhenghuayu capsule also can be used for the treatment of myocardial fibrosis after myocardial infarction.